Rosalind Sulaiman
Internal Medicine · Buffalo, NYNPI 1891954012
Payments from drug & device makers
Across 144 payments — averaging $1007.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kedplasma LLC$144K
- AstraZeneca$184
- Gilead$167
- Astellas Pharma US Inc$125
- Exact Sciences$120
- Pfizer$82
- plus $184 from 7 others
What the payments were for
- Consulting fees$144,25099%
- Food & beverage$8621%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kedplasma LLC | 118 | $144,250 |
| AstraZeneca | 5 | $184 |
| Gilead | 2 | $167 |
| Astellas Pharma US Inc | 1 | $125 |
| Exact Sciences | 1 | $120 |
| Pfizer | 5 | $82 |
| Amgen(2 entities) | 4 | $61 |
| Johnson & Johnson | 2 | $33 |
| Lilly USA, LLC | 2 | $30 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yeztugo$150
- Veozah$125
- AIRSUPRA$125
- The Cologuard Plus Collection Kit$120
How this compares
$145,112 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 65 | $64,022 |
| TrulicityDulaglutide | 59 | $56,651 |
| EliquisApixaban | 76 | $55,647 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,562 |
| MyrbetriqMirabegron | 17 | $7,748 |
| XareltoRivaroxaban | 12 | $7,056 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,168 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $5,706 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 131 | $3,827 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $3,338 |
| Atorvastatin Calcium | 280 | $3,098 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 90 | $2,648 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $2,043 |
| Levothyroxine Sodium | 203 | $1,927 |
| Gabapentin | 130 | $1,734 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $15 | $64,02265 claims |
| Lilly USA, LLCTrulicity | $30 | $56,65159 claims |
| PfizerEliquis | $82 | $55,64776 claims |
| Astellas Pharma US IncMyrbetriq | $125 | $7,74817 claims |
| Johnson & JohnsonXarelto | $33 | $7,05612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Buffalo
- Nicholas RobinsonBuffalo$2.9M
- Anthony MartinezBuffalo$1.7M
- Joseph IzzoBuffalo$1.6M
- Sanjay SethiBuffalo$1.4M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.